Aquinnah Pharma Receives NINDS Grant for ALS Drug Development

Cambridge, MA-based Aquinnah Pharmaceuticals has been awarded $680,000 from the National Institute of Neurological Disorders and Stroke (NINDS) for the research and development of ALS drugs. Founded in 2014 and building in work from the laboratory of co-founder Benjamin Wolozin at Boston University, the company focuses on creating drugs aimed to disrupt TDP-43 aggregation and stress granule formation. This announcement follows on the footsteps of another grant received from the ALS Association, to further advance their drug discovery program for ALS (see July 2015 news).

Read the press release here.

disease-als topic-preclinical topic-randd
Share this: